Kurse um 15 Minuten verzögert
Die Reihe ist auf die aktuelle Aktienzahl nach Splits umgerechnet; Dividenden sind nicht im Kurs enthalten
| Datum | Eröffnung | Hoch | Tief | Schluss | Volumen, Stück |
|---|---|---|---|---|---|
| 15. September 2026 | 260,00 | 264,81 | 257,80 | 263,04 | 5 Mio. |
| 14. September 2026 | 261,67 | 264,65 | 260,10 | 261,77 | 5 Mio. |
| 11. September 2026 | 253,92 | 259,61 | 253,92 | 257,12 | 4 Mio. |
| 10. September 2026 | 251,23 | 255,31 |
Auf Basis der Berichte bis 31. März 2026
AbbVie is a drug maker that has lived through the patent expiry of its flagship medicine and replaced it with a next generation.
For years the base was Humira, an autoimmune treatment and one of the best-selling drugs in the industry's history. Its patent expiry and the arrival of biosimilars tested the company's durability: revenue from that product declines, and the question was what would replace it.
The replacement is a next generation of medicines in the same field, plus neuroscience, oncology and aesthetics following the Allergan acquisition, including Botox. That diversification leaves the company less dependent on a single product than it historically was.
The industry model is unchanged: high margins under patent protection, a sharp fall once it ends, so value rests on the pipeline and on deals for external assets. AbbVie pays a dividend that is high by sector standards and is held for cash flow.
Adresse:1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064, US
| 992 Mio. |
| ABTAbbott Laboratories | 102,38 | +1,50 % | 848 Mio. |
| VRTXVertex Pharmaceuticals Incorporated | 513,25 | −0,20 % | 582 Mio. |
| BMYBristol-Myers Squibb Company | 63,15 | −0,71 % | 575 Mio. |
| AZNAstraZeneca PLC | 165,60 | +1,66 % | 573 Mio. |
| 249,74 |
| 255,00 |
| 4 Mio. |
| 09. September 2026 | 247,73 | 251,18 | 246,77 | 250,91 | 4 Mio. |
| 08. September 2026 | 251,84 | 254,62 | 248,41 | 248,78 | 6 Mio. |
| 04. September 2026 | 257,96 | 258,91 | 255,58 | 256,46 | 5 Mio. |
| 03. September 2026 | 264,00 | 264,25 | 257,14 | 260,21 | 3 Mio. |
| 02. September 2026 | 262,70 | 262,97 | 257,70 | 261,72 | 4 Mio. |
| 01. September 2026 | 260,99 | 262,27 | 257,79 | 259,99 | 4 Mio. |
| 31. August 2026 | 254,17 | 258,24 | 252,33 | 256,42 | 4 Mio. |
| 28. August 2026 | 258,67 | 259,00 | 255,08 | 255,48 | 3 Mio. |
| 27. August 2026 | 260,81 | 262,50 | 257,25 | 258,15 | 5 Mio. |
| 26. August 2026 | 264,60 | 265,00 | 260,31 | 262,90 | 3 Mio. |
| 25. August 2026 | 264,50 | 266,91 | 263,03 | 265,79 | 4 Mio. |
| 24. August 2026 | 263,99 | 266,04 | 262,07 | 264,52 | 4 Mio. |
| 21. August 2026 | 260,70 | 266,84 | 260,10 | 264,96 | 5 Mio. |
| 20. August 2026 | 265,69 | 265,93 | 260,48 | 261,83 | 5 Mio. |
| 19. August 2026 | 261,51 | 266,97 | 259,55 | 265,97 | 6 Mio. |
| 18. August 2026 | 253,93 | 259,18 | 252,41 | 258,92 | 5 Mio. |